HC Wainwright Reaffirms Buy Rating for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $50.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 38.16% from the stock’s current price.

Several other equities research analysts have also recently issued reports on ASMB. Citigroup began coverage on shares of Assembly Biosciences in a research report on Wednesday, September 24th. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, October 8th. Mizuho set a $40.00 price objective on Assembly Biosciences and gave the stock an “outperform” rating in a research note on Thursday, November 20th. Citizens Jmp assumed coverage on Assembly Biosciences in a report on Wednesday, September 24th. They set an “outperform” rating and a $38.00 price objective on the stock. Finally, JMP Securities assumed coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They set a “market outperform” rating and a $38.00 target price for the company. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Assembly Biosciences Stock Up 2.6%

ASMB traded up $0.93 during trading hours on Monday, reaching $36.19. 116,480 shares of the company’s stock traded hands, compared to its average volume of 75,194. The firm has a 50-day moving average price of $33.27 and a 200 day moving average price of $25.46. The firm has a market capitalization of $572.53 million, a PE ratio of -7.56 and a beta of 1.14. Assembly Biosciences has a 52-week low of $7.75 and a 52-week high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.22). The company had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $7.46 million. Assembly Biosciences had a negative net margin of 103.65% and a negative return on equity of 59.01%. Equities analysts predict that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Institutional Trading of Assembly Biosciences

A number of institutional investors have recently modified their holdings of ASMB. Farallon Capital Management LLC purchased a new stake in shares of Assembly Biosciences during the third quarter valued at $31,426,000. RA Capital Management L.P. acquired a new stake in shares of Assembly Biosciences during the third quarter worth about $26,122,000. Commodore Capital LP acquired a new stake in shares of Assembly Biosciences during the third quarter worth about $25,600,000. Parkman Healthcare Partners LLC purchased a new stake in Assembly Biosciences in the third quarter valued at approximately $6,425,000. Finally, Vanguard Group Inc. increased its holdings in Assembly Biosciences by 97.8% in the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after buying an additional 248,287 shares during the period. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.